[HTML][HTML] Biomarker-targeted therapies in non–small cell lung cancer: current status and perspectives
H Guo, J Zhang, C Qin, H Yan, T Liu, H Hu, S Tang… - Cells, 2022 - mdpi.com
Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …
[HTML][HTML] Fibroblast growth factor receptor 1-4 genetic aberrations as clinically relevant biomarkers in squamous cell lung cancer
J Moes-Sosnowska… - Frontiers in Oncology, 2022 - frontiersin.org
Fibroblast growth factor receptor (FGFR) inhibitors (FGFRis) are a potential therapeutic
option for squamous non-small cell lung cancer (Sq-NSCLC). Because appropriate patient …
option for squamous non-small cell lung cancer (Sq-NSCLC). Because appropriate patient …
Current development of pyrazole–azole hybrids with anticancer potential
S Zhang, Y Ye, Q Zhang, Y Luo, ZC Wang… - Future Medicinal …, 2023 - Taylor & Francis
Chemotherapy is a critical treatment modality for cancer patients, but multidrug resistance
remains one of the major challenges in cancer therapy, creating an urgent need for the …
remains one of the major challenges in cancer therapy, creating an urgent need for the …
[HTML][HTML] Transcriptome Analysis of the Inhibitory Effects of 20 (S)-Protopanaxadiol on NCI-H1299 Non-Small Cell Lung Cancer Cells
Z Cong, X Zhang, Z Lv, J Jiang, L Wang, J Li, J Wang… - Molecules, 2023 - mdpi.com
Lung cancer seriously threatens human health. To explore the molecular mechanism of 20
(S)-Protopanaxadiol (PPD) on human non-small cell lung cancer cells, we investigated the …
(S)-Protopanaxadiol (PPD) on human non-small cell lung cancer cells, we investigated the …
[HTML][HTML] Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is Modulated by Vitamin D
A Piotrowska, JI Nowak, JM Wierzbicka… - International Journal of …, 2024 - mdpi.com
Regardless of the unprecedented progress in malignant melanoma treatment strategies and
clinical outcomes of patients during the last twelve years, this skin cancer remains the most …
clinical outcomes of patients during the last twelve years, this skin cancer remains the most …
[HTML][HTML] FGFR inhibitors combined with nab-paclitaxel-A promising strategy to treat non-small cell lung cancer and overcome resistance
F Ma, X Zhu, Y Niu, A Nai, S Bashir, Y Xiong… - Frontiers in …, 2023 - frontiersin.org
Lung cancer has high morbidity and mortality rates worldwide, and NSCLC accounts for
85% of all lung cancer cases. Despite the development of targeted therapies and …
85% of all lung cancer cases. Despite the development of targeted therapies and …
[PDF][PDF] MOLECULAR MECHANISMS OF TUMOR CELL RESISTANCE TO THE FGFR KINASE INHIBITOR
G Branch - 2023 - repolis.bg.polsl.pl
Pragnę serdecznie podziękować mojej Promotorce Pani prof. dr hab. Katarzynie Lisowskiej
za umożliwienie mi rozpoczęcia kariery naukowej i za pomoc w utrzymaniu się na tej …
za umożliwienie mi rozpoczęcia kariery naukowej i za pomoc w utrzymaniu się na tej …
Signaling Mechanisms Driving Parp Inhibitor Resistance in High Grade Serous Ovarian Cancer
AN McMellen - 2022 - search.proquest.com
High grade serous ovarian cancer (HGSOC) is the deadliest gynecologic malignancy due in-
part to the lack of therapeutic options for chemotherapy resistant disease. Poly (ADP)-ribose …
part to the lack of therapeutic options for chemotherapy resistant disease. Poly (ADP)-ribose …